|
1
|
Corson TW and Crews CM: Molecular
understanding and modern application of traditional medicines:
Triumphs and trials. Cell. 130:769–774. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Meng C, Zhu H, Song H, Wang Z, Huang G, Li
D, Ma Z and Ma J, Qin Q, Sun X and Ma J: Targets and molecular
mechanisms of triptolide in cancer therapy. Chin J Cancer Res.
26:622–626. 2014.PubMed/NCBI
|
|
3
|
Xiong J, Su T, Qu Z, Yang Q, Wang Y, Li J
and Zhou S: Triptolide has anticancer and chemosensitization
effects by down-regulating Akt activation through the MDM2/REST
pathway in human breast cancer. Oncotarget. 7:23933–23946. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cheng X, Shi W, Zhao C, Zhang D, Liang P,
Wang G and Lu L: Triptolide sensitizes human breast cancer cells to
tumor necrosis factor-α-induced apoptosis by inhibiting activation
of the nuclear factor-κB pathway. Mol Med Rep. 13:3257–3264. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ateba SB, Ngeu ST, Mvondo MA, Tchoumtchoua
J, Awounfack CF, Krenn L and Njamen D: Natural terpenoids against
female breast cancer: A 5-year recent research. Curr Med Chem.
25:3162–3213. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sørlie T, Perou CM, Tibshirani R, Aas T,
Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey
SS, et al: Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical implications. Proc Natl
Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sims AH, Howell A, Howell SJ and Clarke
RB: Origins of breast cancer subtypes and therapeutic implications.
Nat Clin Pract Oncol. 4:516–525. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Peddi PF, Ellis MJ and Ma C: Molecular
basis of triple negative breast cancer and implications for
therapy. Int J Breast Cancer. 2012:2171852012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liedtke C, Mazouni C, Hess KR, André F,
Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B,
Green M, et al: Response to neoadjuvant therapy and long-term
survival in patients with triple-negative breast cancer. J Clin
Oncol. 26:1275–1281. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shao H, Ma J, Guo T and Hu R: Triptolide
induces apoptosis of breast cancer cells via a mechanism associated
with the Wnt/β-catenin signaling pathway. Exp Ther Med. 8:505–508.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tan BJ, Tan BH and Chiu GN: Effect of
triptolide on focal adhesion kinase and survival in MCF-7 breast
cancer cells. Oncol Rep. 26:1315–1321. 2011.PubMed/NCBI
|
|
12
|
Yang A, Qin S, Schulte BA, Ethier SP, Tew
KD and Wang GY: MYC inhibition depletes cancer stem-like cells in
triple-negative breast cancer. Cancer Res. 77:6641–6650. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tang Y, Wang J, Cheng J and Wang L:
Antiestrogenic Activity of Triptolide in Human Breast Cancer Cells
MDA-MB-231 and Immature Female Mouse. Drug Dev Res. 78:164–169.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xi C, Peng S, Wu Z, Zhou Q and Zhou J:
Toxicity of triptolide and the molecular mechanisms involved.
Biomed Pharmacother. 90:531–541. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li XJ, Jiang ZZ and Zhang LY: Triptolide:
Progress on research in pharmacodynamics and toxicology. J
Ethnopharmacol. 155:67–79. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhao H, Shi P, Deng M, Jiang Z, Li Y,
Kannappan V, Wang W, Li P and Xu B: Low dose triptolide reverses
chemoresistance in adult acute lymphoblastic leukemia cells via
reactive oxygen species generation and DNA damage response
disruption. Oncotarget. 7:85515–85528. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim SH, Kang JG, Kim CS, Ihm SH, Choi MG,
Yoo HJ and Lee SJ: Synergistic cytotoxicity of BIIB021 with
triptolide through suppression of PI3K/Akt/mTOR and NF-κB signal
pathways in thyroid carcinoma cells. Biomed Pharmacother. 83:22–32.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Qiao Z, He M, He MU, Li W, Wang X, Wang Y,
Kuai Q, Li C, Ren S and Yu Q: Synergistic antitumor activity of
gemcitabine combined with triptolide in pancreatic cancer cells.
Oncol Lett. 11:3527–3533. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li H, Pan GF, Jiang ZZ, Yang J, Sun LX and
Zhang LY: Triptolide inhibits human breast cancer MDA-MB-231 cell
growth via downregulation of the ERα-mediated signaling pathway.
Acta Pharmacol Sin. 36:606–613. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Peiró G, Adrover E, Sánchez-Tejada L,
Lerma E, Planelles M, Sánchez-Payá J, Aranda FI, Giner D and
Gutiérrez-Aviñó FJ: Increased insulin-like growth factor-1 receptor
mRNA expression predicts poor survival in immunophenotypes of early
breast carcinoma. Mod Pathol. 24:201–208. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Knowlden JM, Hutcheson IR, Barrow D, Gee
JM and Nicholson RI: Insulin-like growth factor-I receptor
signaling in tamoxifen-resistant breast cancer: a supporting role
to the epidermal growth factor receptor. Endocrinology.
146:4609–4618. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yamamoto K, Ichijo H and Korsmeyer SJ:
BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal
protein kinase pathway normally activated at G(2)/M. Mol Cell Biol.
19:8469–8478. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ciriello G, Gatza ML, Beck AH, Wilkerson
MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, et
al: TCGA research network, perou cm. comprehensive molecular
portraits of invasive lobular breast cancer. Cell. 163:506–519.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cancer Genome Atlas Network: Comprehensive
molecular portraits of human breast tumours. Nature. 90:61–70.
2012. View Article : Google Scholar
|
|
25
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: an open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen J, Bardes EE, Aronow BJ and Jegga AG:
ToppGene Suite for gene list enrichment analysis and candidate gene
prioritization. Nucleic Acids Res 37(Web Server issue). W305–W311.
2009. View Article : Google Scholar
|
|
27
|
Elstrodt F, Hollestelle A, Nagel JH, Gorin
M, Wasielewski M, van den Ouweland A, Merajver SD, Ethier SP and
Schutte M: BRCA1 mutation analysis of 41 human breast cancer cell
lines reveals three new deleterious mutants. Cancer Res 1:.
66:41–45. 2006. View Article : Google Scholar
|
|
28
|
Wan CK, Wang C, Cheung HY, Yang M and Fong
WF: Triptolide induces Bcl-2 cleavage and mitochondria dependent
apoptosis in p53-deficient HL-60 cells. Cancer Lett. 241:31–41.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chueh FS, Chen YL, Hsu SC, Yang JS, Hsueh
SC, Ji BC, Lu HF and Chung JG: Triptolide induced DNA damage in
A375.S2 human malignant melanoma cells is mediated via reduction of
DNA repair genes. Oncol Rep. 29:613–618. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Davison Z, de Blacquière GE, Westley BR
and May FEB: Insulin-like Growth Factor-Dependent Proliferation and
Survival of Triple-Negative Breast Cancer Cells: Implications for
Therapy. Neoplasia. 13:504–515. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jeon JH, Kim SK, Kim HJ, Chang J, Ahn CM
and Chang YS: Insulin-like growth factor-1 attenuates
cisplatin-induced gammaH2AX formation and DNA double-strand breaks
repair pathway in non-small cell lung cancer. Cancer Lett.
272:232–241. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Railo MJ, von Smitten K and Pekonen F: The
prognostic value of insulin-like growth factor-I in breast cancer
patients. Results of a follow-up study on 126 patients. Eur J
Cancer 30A. 307–311. 1994. View Article : Google Scholar
|
|
33
|
Hartog H, Horlings HM, van der Vegt B,
Kreike B, Ajouaou A, van de Vijver MJ, Marike Boezen H, de Bock GH,
van der Graaf WT and Wesseling J: Divergent effects of insulin-like
growth factor-1 receptor expression on prognosis of estrogen
receptor positive versus triple negative invasive ductal breast
carcinoma. Breast Cancer Res Treat. 129:725–736. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Martin JL and Baxter RC: Expression of
insulin-like growth factor binding protein-2 by MCF-7 breast cancer
cells is regulated through the phosphatidylinositol
3-kinase/AKT/mammalian target of rapamycin pathway. Endocrinology.
148:2532–2541. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang Y, Moerkens M, Ramaiahgari S, de
Bont H, Price L, Meerman J and van de Water B: Elevated
insulin-like growth factor 1 receptor signaling induces
antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling
routes. Breast Cancer Res. 13:R522011. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jones HE, Goddard L, Gee JM, Hiscox S,
Rubini M, Barrow D, Knowlden JM, Williams S, Wakeling AE and
Nicholson RI: Insulin-like growth factor-I receptor signalling and
acquired resistance to gefitinib (ZD1839; Iressa) in human breast
and prostate cancer cells. Endocr Relat Cancer. 11:793–814. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Riedemann J and Macaulay VM: IGF1R
signalling and its inhibition. Endocr Relat Cancer. 13 (Suppl
1):S33–S43. 2006. View Article : Google Scholar : PubMed/NCBI
|
